Simplex Trading
ACRS icon

Simplex Trading’s Aclaris Therapeutics ACRS Stock Holding History

Simplex Trading’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$42.1K Sell
11,216
-5,452
-33% -$18.4K ﹤0.01% 6057
2025
Q4 		$50.2K Buy
+16,668
New +$42.1K ﹤0.01% 5652
2025
Q3 		– Sell
-1,336
Closed -$2.33K – 8933
2025
Q2 		$1K Buy
+1,336
New +$1.81K ﹤0.01% 8243
2025
Q1 		– Sell
-6,695
Closed -$14.3K – 8380
2024
Q4 		$16K Buy
6,695
+5,610
+517% +$14K ﹤0.01% 6835
2024
Q3 		$1K Sell
1,085
-9,081
-89% -$11.1K ﹤0.01% 8119
2024
Q2 		$11K Sell
10,166
-17,898
-64% -$21K ﹤0.01% 7339
2024
Q1 		$34K Buy
+28,064
New +$33.5K ﹤0.01% 6626
2023
Q4 		– Sell
-29,424
Closed -$89.8K – 8660
2023
Q3 		$201K Buy
29,424
+27,081
+1,156% +$231K ﹤0.01% 4344
2023
Q2 		$24K Sell
2,343
-123,284
-98% -$1.12M ﹤0.01% 6566
2023
Q1 		$1.02M Buy
125,627
+125,534
+134,983% +$1.59M ﹤0.01% 2575
2022
Q4 		$1K Sell
93
-879
-90% -$14.1K ﹤0.01% 8738
2022
Q3 		$15K Buy
+972
New +$15.3K ﹤0.01% 7802
2022
Q2 		– Sell
-12,482
Closed -$175K – 9820
2022
Q1 		$215K Sell
12,482
-11,717
-48% -$160K ﹤0.01% 5056
2021
Q4 		$351K Buy
24,199
+19,956
+470% +$302K ﹤0.01% 4327
2021
Q3 		$73K Sell
4,243
-296
-7% -$4.75K ﹤0.01% 7041
2021
Q2 		$79K Sell
4,539
-9,434
-68% -$214K ﹤0.01% 7057
2021
Q1 		$352K Buy
13,973
+10,076
+259% +$197K ﹤0.01% 3915
2020
Q4 		$25K Buy
3,897
+701
+22% +$2.96K ﹤0.01% 6810
2020
Q3 		$8K Buy
3,196
+2,681
+521% +$6K ﹤0.01% 6878
2020
Q2 		$0 Buy
+515
New +$690 ﹤0.01% 7498
2020
Q1 		– Sell
-252
Closed -$343 – 7500
2019
Q4 		$0 Sell
252
-1,662
-87% -$2.75K ﹤0.01% 7190
2019
Q3 		$2K Sell
1,914
-2,734
-59% -$3.88K ﹤0.01% 6882
2019
Q2 		$10K Buy
4,648
+2,638
+131% +$14.4K ﹤0.01% 6087
2019
Q1 		$12K Buy
2,010
+1,640
+443% +$10.9K ﹤0.01% 6027
2018
Q4 		$2K Buy
+370
New +$3.81K ﹤0.01% 6524

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Simplex Trading's ACRS Position: Q1 2026 in Review

Simplex Trading reduced its Aclaris Therapeutics (ACRS) stake by 33% in Q1 2026, selling an estimated $18.4K and leaving 11,216 shares worth $42.1K. The position accounts for ﹤0.01% of the portfolio, ranked #6057.

Simplex Trading first reported a position in ACRS in Q4 2018 and has held it in 25 quarters since. The position peaked at $1.02M in Q1 2023. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • Simplex Trading held 11,216 shares of Aclaris Therapeutics worth $42.1K as of Q1 2026.
  • Simplex Trading sold 5,452 Aclaris Therapeutics shares in Q1 2026, an estimated $18.4K.
  • Aclaris Therapeutics made up ﹤0.01% of Simplex Trading's portfolio in Q1 2026, its #6057 holding.
  • Simplex Trading first reported a position in Aclaris Therapeutics in Q4 2018 and has held it in 25 quarters since.
  • Simplex Trading's Aclaris Therapeutics position peaked at $1.02M in Q1 2023.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on Simplex Trading's 13F filing for Q1 2026, filed 14 May 2026.